Quinazolines

DrugDrug NameDrug Indication
DB00457PrazosinFor treatment of hypertension, symptomatic benign prostatic hyperplasia, and severe congestive heart failure. May also be used alone or in combination with β-blockers in the preoperative management of signs and symptoms of pheochromocytoma.
DB00524MetolazoneFor the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.
DB00530ErlotinibFor the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
DB00590DoxazosinFor treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.
DB01157TrimetrexateFor use, with concurrent leucovorin administration (leucovorin protection), as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS). Also used to treat several types of cancer including colon cancer.
DB01162TerazosinFor the treatment of symptomatic BPH and mild to moderate hypertension.
DB04833MethaqualoneFor the treatment of insomnia, and as a sedative and muscle relaxant.
DB04866HalofuginoneFor the treatment of scleroderma, cancer, and restenosis.
DB05232TetrodotoxinFor the treatment of chronic and breakthrough pain in advanced cancer patients as well as for the treatment of opioid dependence.
DB06350ElinogrelInvestigated for use/treatment in cardiovascular disorders and myocardial infarction.
DB08882LinagliptinLinagliptin is used for the management of type 2 diabetes mellitus.
DB09054IdelalisibIdelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.
DB11670SP-8203Not Available
DB11910MK-0249Not Available
DB11963DacomitinibNot Available
DB12367SelurampanelNot Available
DB12465KetanserinNot Available
DB12673ATX-914Not Available
DrugDrug NameTargetType
DB00457PrazosinAlpha-1A adrenergic receptortarget
DB00457PrazosinAlpha-1B adrenergic receptortarget
DB00457PrazosinAlpha-1D adrenergic receptortarget
DB00457PrazosinPotassium voltage-gated channel subfamily H member 2target
DB00457PrazosinPotassium voltage-gated channel subfamily H member 6target
DB00457PrazosinPotassium voltage-gated channel subfamily H member 7target
DB00457PrazosinAlpha-1-acid glycoprotein 1carrier
DB00457PrazosinSolute carrier family 22 member 2transporter
DB00457PrazosinSolute carrier family 22 member 1transporter
DB00457PrazosinSolute carrier family 22 member 3transporter
DB00457PrazosinMultidrug resistance protein 1transporter
DB00457PrazosinATP-binding cassette sub-family G member 2transporter
DB00457PrazosinCytochrome P450 1A1enzyme
DB00457PrazosinAlpha-2A adrenergic receptortarget
DB00457PrazosinAlpha-2B adrenergic receptortarget
DB00524MetolazoneSolute carrier family 12 member 3target
DB00530ErlotinibEpidermal growth factor receptortarget
DB00530ErlotinibCytochrome P450 3A4enzyme
DB00530ErlotinibATP-binding cassette sub-family G member 2transporter
DB00530ErlotinibMultidrug resistance protein 1transporter
DB00530ErlotinibNuclear receptor subfamily 1 group I member 2target
DB00530ErlotinibCytochrome P450 3A5enzyme
DB00530ErlotinibCytochrome P450 1A1enzyme
DB00530ErlotinibCytochrome P450 1A2enzyme
DB00530ErlotinibCytochrome P450 1B1enzyme
DB00530ErlotinibCytochrome P450 2D6enzyme
DB00530ErlotinibCytochrome P450 2C8enzyme
DB00530ErlotinibUDP-glucuronosyltransferase 1-1enzyme
DB00530ErlotinibSerum albumincarrier
DB00530ErlotinibAlpha-1-acid glycoprotein 1carrier
DB00530ErlotinibSolute carrier organic anion transporter family member 2B1transporter
DB00530ErlotinibCYP3Aenzyme
DB00590DoxazosinAlpha-1A adrenergic receptortarget
DB00590DoxazosinAlpha-1B adrenergic receptortarget
DB00590DoxazosinAlpha-1D adrenergic receptortarget
DB00590DoxazosinPotassium voltage-gated channel subfamily H member 2target
DB00590DoxazosinPotassium voltage-gated channel subfamily H member 6target
DB00590DoxazosinPotassium voltage-gated channel subfamily H member 7target
DB00590DoxazosinAlpha-1-acid glycoprotein 1carrier
DB00590DoxazosinMultidrug resistance protein 1transporter
DB00590DoxazosinCytochrome P450 2C19enzyme
DB00590DoxazosinCytochrome P450 2D6enzyme
DB01157TrimetrexateDihydrofolate reductasetarget
DB01162TerazosinAlpha-1A adrenergic receptortarget
DB01162TerazosinAlpha-1B adrenergic receptortarget
DB01162TerazosinAlpha-1D adrenergic receptortarget
DB01162TerazosinPotassium voltage-gated channel subfamily H member 2target
DB01162TerazosinPotassium voltage-gated channel subfamily H member 6target
DB01162TerazosinPotassium voltage-gated channel subfamily H member 7target
DB01162TerazosinMultidrug resistance protein 1transporter
DB04833MethaqualoneCytochrome P450 3A4enzyme
DB04866HalofuginoneCollagen alpha-1(I) chaintarget
DB04866Halofuginone72 kDa type IV collagenasetarget
DB05232TetrodotoxinSodium channel protein type 1 subunit alphatarget
DB05232TetrodotoxinSodium channel protein type 2 subunit alphatarget
DB05232TetrodotoxinSodium channel protein type 3 subunit alphatarget
DB05232TetrodotoxinSodium channel protein type 8 subunit alphatarget
DB06350ElinogrelP2Y purinoceptor 12target
DB08882LinagliptinDipeptidyl peptidase 4target
DB08882LinagliptinCytochrome P450 3A4enzyme
DB08882LinagliptinMultidrug resistance protein 1transporter
DB09054IdelalisibPhosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (P110δ)target
DB09054IdelalisibATP-binding cassette sub-family G member 2transporter
DB09054IdelalisibMultidrug resistance protein 1transporter
DB09054IdelalisibAldehyde oxidaseenzyme
DB09054IdelalisibUDP-glucuronosyltransferase 1A4enzyme
DB09054IdelalisibUDP-glucuronosyltransferase 1A1enzyme
DB09054IdelalisibCytochrome P450 2C8enzyme
DB09054IdelalisibCytochrome P450 2C19enzyme
DB09054IdelalisibCytochrome P450 2B6enzyme
DB09054IdelalisibCytochrome P450 3A4enzyme
DB09054IdelalisibSolute carrier organic anion transporter family member 1B1transporter
DB09054IdelalisibSolute carrier organic anion transporter family member 1B3transporter
DB09054IdelalisibCytochrome P450 3A5enzyme
DB09054IdelalisibCytochrome P450 3A43enzyme
DB09054IdelalisibCytochrome P450 3A7enzyme
DB12465Ketanserin5-hydroxytryptamine receptor 2Atarget